BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 3301601)

  • 1. [Theophylline--once or twice daily?].
    Schoch C; Menz G; Virchow C
    Fortschr Med; 1987 May; 105(16):319-22. PubMed ID: 3301601
    [No Abstract]   [Full Text] [Related]  

  • 2. [Use of a new delayed-release anhydrous theophylline by single daily administration in the treatment of reversible bronchial obstruction. Comparison with a delayed-release preparation administered twice daily].
    Baronti A; Verdiani P; Di Carlo S
    Clin Ter; 1987 Sep; 122(6):437-40. PubMed ID: 2972456
    [No Abstract]   [Full Text] [Related]  

  • 3. [Bamifylline in the treatment of chronic bronchial obstruction: a controlled clinico-functional study versus an anhydrous theophylline administered once a day].
    Caputi M; Cautiero V; Aliberti M; Monici Preti PA; Oliani C
    Arch Monaldi Mal Torace; 1988; 43(5):409-21. PubMed ID: 3079283
    [No Abstract]   [Full Text] [Related]  

  • 4. [Prescription of Theostat 300 as a single evening dose].
    Germouty J; Bida C; Moreau L
    Rev Pneumol Clin; 1987; 43(5):262-5. PubMed ID: 3324266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic action of a new xanthine derivative in respiratory pathology].
    Cesco G; Biondi T; Mazzini R
    Clin Ter; 1986 Aug; 118(4):253-7. PubMed ID: 3530620
    [No Abstract]   [Full Text] [Related]  

  • 6. [Comparison of two long-acting theophylline preparations in daily evening administration].
    Holzer R
    Wien Med Wochenschr; 1993; 143(2):37-42. PubMed ID: 8488685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dose titration with Euphylong following prior determination of serum concentration in the steady state].
    Schnabel D; von Treufels S; Oellerich M; Böttger HC; Sybrecht GW
    Pneumologie; 1990 Feb; 44 Suppl 1():287-8. PubMed ID: 2367392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of Unilair in general practice conditions. Treatment of chronic obstructive airway diseases with theophylline].
    Gregori P; Hader S; Samiri H; Wiemann M; Yousif MJ; Kiebart M
    Fortschr Med; 1997 Jan; 115(1-2):54-5. PubMed ID: 9102383
    [No Abstract]   [Full Text] [Related]  

  • 9. [The effect of theophylline in slow-release or regular preparations in chronic obstructive lung disease. A double-blind study comparing Nuelin Depot, Nuelin and placebo].
    Aamodt T; Lien JT; Haaversen O; Osmundsen K
    Tidsskr Nor Laegeforen; 1983 Jun; 103(17-18):1397-9. PubMed ID: 6353660
    [No Abstract]   [Full Text] [Related]  

  • 10. Clenbuterol and salbutamol in the symptomatic treatment of patients with reversible airways obstruction.
    Jaffé G; Grimshaw JJ
    Pharmatherapeutica; 1983; 3(7):492-5. PubMed ID: 6366806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A comparative study of Unixan administered once daily and Theo-Dur administered twice daily].
    Dahl R; Pedersen B
    Ugeskr Laeger; 1986 Sep; 148(40):2548-51. PubMed ID: 3535197
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term therapy with sustained-release theophylline.
    Myhre KI; Arnulf V; Walstad RA
    Pharmatherapeutica; 1985; 4(2):92-7. PubMed ID: 3903782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Obstructive airway diseases. Basic therapy with pure theophylline in retard form].
    Pollert I
    Fortschr Med; 1982 Mar; 100(12):547-50. PubMed ID: 7042500
    [No Abstract]   [Full Text] [Related]  

  • 14. [Pirenzepine in the prevention of gastric intolerance to drugs used in pulmonary pathology].
    Guarino C; Cautiero V; Borrelli G; De los Rios B; Marcatili S; Valentini P
    Minerva Dietol Gastroenterol; 1988; 34(2):129-34. PubMed ID: 3050611
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapy of obstructive respiratory tract diseases. Study of afonilum retard in 3,512 patients].
    Eichhorn J; Perré R
    Med Welt; 1982 Dec; 33(50):1834-7. PubMed ID: 6762480
    [No Abstract]   [Full Text] [Related]  

  • 16. [Polysomnographic measurements in early and late administration (18.00 vs. 22.00 hours) of retarded theophylline in bronchial asthma].
    Rühle KH; Horn H; Hagenmeier A; Würtemberger G; Schmitz-Schumann M; Matthys H
    Prax Klin Pneumol; 1987 May; 41(5):180-6. PubMed ID: 3299354
    [No Abstract]   [Full Text] [Related]  

  • 17. Steady-state pharmacokinetics of two sustained-release theophylline products during once-daily and twice-daily dosing.
    Armstrong EP; Nako N; Plezia PM; Kramer TH; Jones WN
    Clin Pharm; 1987 Oct; 6(10):800-4. PubMed ID: 3505842
    [No Abstract]   [Full Text] [Related]  

  • 18. Serum theophylline and ventilatory function in chronic obstructive lung disease. Comparison between two slow-release formulations of theophylline.
    Tantucci C; Grassi V; Verdecchia P; Cornelli U; Sorbini CA
    Int J Clin Pharmacol Ther Toxicol; 1985 Oct; 23(10):560-4. PubMed ID: 3905630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unequal twice-daily, sustained-release theophylline dosing in chronic obstructive pulmonary disease.
    Bruguerolle B; Philip-Joet F; Parrel M; Arnaud A
    Chronobiol Int; 1987; 4(3):381-5. PubMed ID: 3315267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of theophylline on lung function and sleep in patients with severe chronic obstructive pulmonary disease].
    Li Y; Liu Y
    Zhonghua Jie He He Hu Xi Za Zhi; 1997 Oct; 20(5):294-8. PubMed ID: 10374456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.